Gene therapy firm MaxCyte misses Q3 revenue estimates

Reuters11-05

Gene therapy firm MaxCyte misses Q3 revenue estimates

Overview

MaxCyte Q3 total revenue of $6.8 mln missed analyst expectations
Core business revenue declined 21% yr/yr to $6.4 mln
Company maintains $158 mln in cash and investments as of Q3 2025

Outlook

MaxCyte reiterates 2025 core revenue guidance as flat to a 10% decline
SPL Program-related revenue expected to be $5 mln for 2025
MaxCyte expects 2025 year-end cash between $152 mln and $155 mln

Result Drivers

SPL PROGRAM GROWTH - SPL Program-related revenue increased significantly, contributing to total revenue
NEW SPL CLIENTS - MaxCyte added new SPL clients, including Moonlight Bio, Adicet Bio, and Anocca AB, increasing total SPL agreements to 32
GROSS MARGIN STRENGTH - Gross margin remains strong at 77%, with a non-GAAP adjusted gross margin of 81%

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$6.40 mln	$8.36 mln (6 Analysts)
Q3 Cash & Investments		$158 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for MaxCyte Inc is $5.72, about 71.9% above its November 4 closing price of $1.61

Press Release: ID:nGNXczkJq

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581272096?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581272096","market":"fut","top_or_hot":-1,"title":"Gene therapy firm MaxCyte misses Q3 revenue estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Gene therapy firm MaxCyte misses Q3 revenue estimates </title></head><body><p><span>Overview</span></p><ul><li><p>MaxCyte Q3 total revenue of $6.8 mln missed analyst expectations</p></li><li><p>Core business revenue declined 21% yr/yr to $6.4 mln</p></li><li><p>Company maintains $158 mln in cash and investments as of Q3 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>MaxCyte reiterates 2025 core revenue guidance as flat to a 10% decline</p></li><li><p>SPL Program-related revenue expected to be $5 mln for 2025</p></li><li><p>MaxCyte expects 2025 year-end cash between $152 mln and $155 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SPL PROGRAM GROWTH - SPL Program-related revenue increased significantly, contributing to total revenue</p></li><li><p>NEW SPL CLIENTS - MaxCyte added new SPL clients, including Moonlight Bio, <a href=\"https://laohu8.com/S/ACET\">Adicet Bio</a>, and Anocca AB, increasing total SPL agreements to 32</p></li><li><p>GROSS MARGIN STRENGTH - Gross margin remains strong at 77%, with a non-GAAP adjusted gross margin of 81%</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$6.40 mln</p></td><td><p>$8.36 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Cash &amp; Investments</p></td><td></td><td><p>$158 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/MXCT\">MaxCyte Inc</a> is $5.72, about 71.9% above its November 4 closing price of $1.61</p></li></ul><p>Press Release: <span>ID:nGNXczkJq</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gene therapy firm MaxCyte misses Q3 revenue estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGene therapy firm MaxCyte misses Q3 revenue estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Gene therapy firm MaxCyte misses Q3 revenue estimates </title></head><body><p><span>Overview</span></p><ul><li><p>MaxCyte Q3 total revenue of $6.8 mln missed analyst expectations</p></li><li><p>Core business revenue declined 21% yr/yr to $6.4 mln</p></li><li><p>Company maintains $158 mln in cash and investments as of Q3 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>MaxCyte reiterates 2025 core revenue guidance as flat to a 10% decline</p></li><li><p>SPL Program-related revenue expected to be $5 mln for 2025</p></li><li><p>MaxCyte expects 2025 year-end cash between $152 mln and $155 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SPL PROGRAM GROWTH - SPL Program-related revenue increased significantly, contributing to total revenue</p></li><li><p>NEW SPL CLIENTS - MaxCyte added new SPL clients, including Moonlight Bio, <a href=\"https://laohu8.com/S/ACET\">Adicet Bio</a>, and Anocca AB, increasing total SPL agreements to 32</p></li><li><p>GROSS MARGIN STRENGTH - Gross margin remains strong at 77%, with a non-GAAP adjusted gross margin of 81%</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$6.40 mln</p></td><td><p>$8.36 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Cash &amp; Investments</p></td><td></td><td><p>$158 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/MXCT\">MaxCyte Inc</a> is $5.72, about 71.9% above its November 4 closing price of $1.61</p></li></ul><p>Press Release: <span>ID:nGNXczkJq</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0PO:1","article_id":"2581272096","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581272096","pubTimestamp":1762348403,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gene therapy firm MaxCyte misses Q3 revenue estimatesOverviewMaxCyte Q3 total revenue of $6.8 mln missed analyst expectationsCore business revenue declined 21% yr/yr to $6.4 mlnCompany maintains $158 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","MXCT":"MaxCyte Inc","ACET":"艾切托","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"基因治疗公司MaxCyte未达到第三季度收入预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACET":0.9,"MXCT":0.9},"content_text":"Gene therapy firm MaxCyte misses Q3 revenue estimates OverviewMaxCyte Q3 total revenue of $6.8 mln missed analyst expectationsCore business revenue declined 21% yr/yr to $6.4 mlnCompany maintains $158 mln in cash and investments as of Q3 2025OutlookMaxCyte reiterates 2025 core revenue guidance as flat to a 10% declineSPL Program-related revenue expected to be $5 mln for 2025MaxCyte expects 2025 year-end cash between $152 mln and $155 mlnResult DriversSPL PROGRAM GROWTH - SPL Program-related revenue increased significantly, contributing to total revenueNEW SPL CLIENTS - MaxCyte added new SPL clients, including Moonlight Bio, Adicet Bio, and Anocca AB, increasing total SPL agreements to 32GROSS MARGIN STRENGTH - Gross margin remains strong at 77%, with a non-GAAP adjusted gross margin of 81%Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$6.40 mln$8.36 mln (6 Analysts)Q3 Cash & Investments$158 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for MaxCyte Inc is $5.72, about 71.9% above its November 4 closing price of $1.61Press Release: ID:nGNXczkJqFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581272096","isCrawlerRequest":true}